Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/79b Bi-specific CAR-T Cells in B Cell Malignancies
NCT05436509Phase 2Terminated
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of bi-4SCAR-CD19/79b T cells in B-cell malignancy, sponsored by Shenzhen Geno-Immune Medical Institute. Started Jun 2026; status: terminated.
02
Drugs
bi-4SCAR-CD19/79b T cells
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on NCT05436509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05436509.